Form 4: Quest Diagnostics SVP Karthik Kuppusamy Reports Stock Transactions

Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposal of company stock through dividend reinvestment, stock purchase plan, and 401(k) plan.

Summary

• Karthik Kuppusamy, a Senior Vice President at Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On January 29, 2025, Kuppusamy acquired 12 shares of common stock at $158.034 per share through a dividend reinvestment plan.
• Kuppusamy also reported disposing of shares, with the specific number not detailed in this summary.
• Following these transactions, Kuppusamy directly owns 9,780 shares of Quest Diagnostics common stock.
• Additionally, Kuppusamy indirectly owns 358 shares through a trust and 1,585 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The reporting person's participation in the dividend reinvestment plan indicates confidence in the company's future performance.
• Continued investment through the stock purchase plan and 401(k) further suggests a positive outlook.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the transactions of a SVP at Quest Diagnostics.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders, reflecting insider confidence or liquidity needs.
• The filing ensures transparency, which is beneficial for all stakeholders.

Key Dates